Urist Marshall sold 4,126 shares of Royalty Pharma plc at $57.88 for −$239k on Sep 28, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
EVP, Research & Investments
EVP, Research & Investments
Filed Sep 30, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$238,812.88Shares × reported price
Shares traded
4,126Class A Ordinary Shares
Price per share
$57.88Reported price. Read footnotes for ranges.
% of reported position traded
50%This security and ownership context
Holdings after
4,126Direct
Trade date
Sep 28, 2026Sell
Filed
Sep 30, 2026, 4:32 PM ET2-day reporting delay
Accession
0001838139-26-000026Code S · Transaction 231871
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 8,252 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

RPRX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RPRX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +4.3%1w ago +0.1%1d ago −0.3%
Returns since7d −2.7%30d +15%90d180d1y

Footnotes in full

F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026.